レッドバイオテクノロジーの市場規模、シェア、成長分析、製品別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

レッドバイオテクノロジーの世界市場規模は、2023年に5,200億米ドルと評価され、2024年の5,527億6,000万米ドルから2032年までには9,011億6,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは6.3％で成長する見通しです。

世界のレッドバイオテクノロジー市場は、慢性感染症や新興感染症の流行の増加に牽引され、大きく拡大しています。この急増は、新規かつ効率的な治療ソリューションを見出すというヘルスケアシステムへの強いプレッシャーを生み出し、モノクローナル抗体、組み換えタンパク質、遺伝子治療などの高度なバイオ医薬品への需要の高まりにつながっています。これを受けて、製薬業界やバイオテクノロジー業界は研究開発に多額の投資を行い、イノベーションを促進しています。さらに、ゲノム解読とバイオインフォマティクスの進歩により、個人の遺伝子プロファイルに合わせた治療法の開発が可能になり、個別化医療への流れが市場を形成しています。その結果、従来の治療法から精密標的治療薬へのシフトが市場の成長を促進し、診断薬と遺伝子標的治療薬の市場情勢を浮き彫りにしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要な市場の考察

• 主要成功要因
• 競合の程度
• 主要な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 技術分析

世界のレッドバイオテクノロジーの市場規模：製品別・CAGR（2025年～2032年）

• 市場概要
• モノクローナル抗体
• ポリクローナル抗体
• 組み換えタンパク質
• ワクチン
• 細胞ベースの免疫療法製品
• 遺伝子治療製品
• 細胞治療製品
• 組織工学製品
• 幹細胞
• 細胞培養
• ウイルスベクター
• 酵素
• キットと試薬
• 動物モデル
• 分子診断
• その他

世界のレッドバイオテクノロジーの市場規模：エンドユーザー別・CAGR（2025年～2032年）

• 市場概要
• 学術調査機関
• CMO・CRO
• 製薬・バイオテクノロジー企業
• その他

世界のレッドバイオテクノロジーの市場規模・CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022年～2024年）

主要企業プロファイル

• Amgen Inc.
• Gilead Sciences, Inc.
• Biogen
• Pfizer Inc.
• Novartis AG
• Hoffmann-La Roche
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• GSK plc.
• AstraZeneca
• Eli Lilly and Company
• Novo Nordisk A/S
• Bayer AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.

結論と提言

Global Red Biotechnology Market size was valued at USD 520.0 billion in 2023 and is poised to grow from USD 552.76 billion in 2024 to USD 901.16 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global red biotechnology market is experiencing significant expansion driven by the increasing prevalence of chronic and emerging infectious diseases. This surge creates intense pressure on healthcare systems to find novel and efficient therapeutic solutions, leading to heightened demand for advanced biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and gene therapies. In response, the pharmaceutical and biotech sectors are channeling substantial investments into research and development, fostering innovation. Additionally, the trend towards personalized medicine is shaping the market, as advancements in genomic sequencing and bioinformatics enable the creation of tailored treatments that align with individual genetic profiles. Consequently, this shift from conventional therapies to precision-targeted drugs enhances market growth, highlighting opportunities for diagnostics and gene-targeted therapies within the red biotechnology landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Red Biotechnology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Red Biotechnology Market Segments Analysis

Global Red Biotechnology Market is segmented by Product, End-User and region. Based on Product, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal models, Molecular diagnostics and Others. Based on End-User, the market is segmented into Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Red Biotechnology Market

The global red biotechnology market is experiencing significant growth due to the rising demand for personalized medicine. Innovations in genomics and diagnostics facilitate the creation of customized treatments that cater to the unique genetic profiles of individuals. Such advancements have paved the way for the development of more effective therapeutic options, including targeted therapies and gene treatments, ultimately improving patient outcomes. As healthcare shifts towards more individualized approaches, the emphasis on precision in medical interventions continues to propel the expansion of the red biotechnology sector, highlighting its pivotal role in advancing modern medicine and enhancing the quality of patient care.

Restraints in the Global Red Biotechnology Market

The substantial expenses linked to the development of red biotechnology products, especially gene therapies and biologics, present a notable challenge within the market. The financial burden of research, clinical trials, and manufacturing processes often restricts the ability of smaller biotech firms to compete effectively. This high cost structure can hinder market expansion, particularly in emerging economies where financial limitations are more pronounced. As a result, the potential for innovation and growth within the industry may be stifled, ultimately affecting the overall advancement and accessibility of red biotechnology solutions on a broader scale.

Market Trends of the Global Red Biotechnology Market

The global red biotechnology market is witnessing a significant surge, propelled by groundbreaking advancements in gene and cell therapies, notably through innovative technologies such as CRISPR and other gene editing tools. This evolution is not only revolutionizing the treatment landscape for genetic disorders but is also paving the way for personalized medicine, thereby enhancing patient outcomes across multiple medical sectors, particularly in oncology. With increasing investments in research and development and a growing number of clinical trials, the demand for targeted therapies is escalating, making red biotechnology a critical component of future healthcare strategies, poised for substantial growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Analysis

Global Red Biotechnology Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell-Based Immunotherapy Products
• Gene Therapy Products
• Cell Therapy Products
• Tissue-Engineered Products
• Stem Cells
• Cell Culture
• Viral Vector
• Enzymes
• Kits and Reagents
• Animal models
• Molecular diagnostics
• Others

Global Red Biotechnology Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Academic Research Institutes
• CMOs & CROs
• Pharmaceutical & Biotechnology Companies
• Others

Global Red Biotechnology Market Size & CAGR (2025-2032)

• North America (Product, End-User)
  • US
  • Canada
• Europe (Product, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations